<style face="normal" font="default" size="100%">1527 ENB-003, an ETBR antagonist, in combination with pembrolizumab, shows promise in microsatellite stable platinum refractory/resistant ovarian cancer: data from the ENBOLDEN-101 phase 1B study</style>

Drupal-HighWire